KYMR's Quality Score fell 2 points on Tue, Nov 10, to 12. Buying slipped from its highest in 20 days (2 chart checks stopped).
Follow KYMR's trial news. Pro members can get an alert when Kymera Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 869% over three years while the S&P 500 rose 80%.
| The chart | Stronger than 96% of stocks |
| Latest filing | 8-K, Oct 29 |
After its last 4 reports it closed +1.3% on average, higher 3 of 4 times.
The company says its cash lasts into 2029 (8-K, Oct 29).
CEO Nello Mainolfi sold 30,000 shares on Oct 1, under a planned sale. 36 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
KYMR is #33 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 33 |
Net income over four quarters: KYMR -$349M, IOVA -$221M, KOD -$242M, RLAY -$294M.
Expected to report Thu Feb 25, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.32 a share, from $0.94.
“This increase was primarily due to increased expenses related to the investment in the Company’s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization.”
KYMR's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The Company does not expect to recognize additional collaboration revenue in 2026.”
From its results filing (SEC filing · Oct 29)
Its share count grew 16% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | +3.7% | +0.1% | +11.2% |
| Aug 5, 2026 | +0.5% | +1.0% | +5.0% |
| Apr 30, 2026 | +4.8% | -0.5% | +5.8% |
Sales grew in three of the last six years, to $39.2M in 2025. It lost money in each of the seven years.
RSI 67.2, MACD above signal, above both averages. Not scored.
2 insiders sold $174M across 7 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KYMR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
“The biotechnology industry is extremely competitive in the race to develop new products.”
KYMR scores 12 today, which Breakaway calls Above Average. It is #33 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 869% over three years while the S&P 500 rose 80%. Shares: 14.7% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KYMR scores 12 today, which Breakaway calls Above Average (11 to 14). That is #33 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KYMR's 12.
2 insiders sold $174M across 7 filings in the last 6 months. No open-market buys on record. The newest is Brian Adams, Chief Legal Officer, who sold $353K on Sep 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.